Skip to content
DataLookout
Menu

NCT07885683

MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Study sites: 0 to 1
    • Collaborators shortened, about 6 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase 1b: Level of Fe in blood
Timeframe: 24 hours post injection
Phase 2 (Imaging Schedule): Dose and Imaging schedule for MSH2IA
Timeframe: 24 hours post injection
Phase 2 (Diagnostic Performance): Diagnostic performance comparison between MSH2IA and SOC
Timeframe: 24 hours post injection

Secondary (1)

Safety and Tolerability of MSH2IA Across All Phases

Arms and interventions

Phase 1b - MSH2IA PharmacokineticsExperimental

Participants enrolled in Phase 1b will receive MSH2IA to evaluate its pharmacokinetic (PK) profile.

Phase 2 - MSH2IA Dose and Diagnostic PerformanceExperimental

Participants enrolled in Phase 2 will receive MSH2IA via subareolar or peritumoral injection to confirm the lowest effective dose, evaluate image timing, and assess the diagnostic performance of a selected dose of MSH2IA.

Combination products: The MagSense® HER2 Imaging Agent (MSH2IA)

Sites

1 site in 1 country

  • Regis Clinical Research LLCMiami, Florida, United States